Shuttle Pharmaceuticals Holdings, Inc. (SHPH) AI Stock Analysis

• Market Cap: $1.60M
• Dividend Yield: N/A
• Average Volume (3M): 960.47K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.02
• Revenue Growth: N/A
• EPS Growth: -7.18%
• Country: US
• Employees: 9
• Sector: Healthcare
• Sector Strength: 72
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): -3.78
• Shares Outstanding: 6,257,693
• 10 Day Avg. Volume: 2,352,298
• 30 Day Avg. Volume: 960,467
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 264.61
• Price to Cash Flow (P/CF): -0.20
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

Shuttle Pharmaceuticals Holdings, Inc. faces significant financial challenges with no revenue and ongoing losses, which heavily impact its stock score. The bearish technical indicators suggest weak market sentiment, although oversold conditions could indicate potential for a rebound. The company's valuation metrics are poor. While recent corporate events offer some strategic progress, financial risks remain high.

Shuttle Pharmaceuticals Holdings, Inc. Business Overview & Revenue Model

Company Description

Shuttle Pharmaceuticals Holdings, Inc. (SHPH) is a biotechnology company focused on developing innovative therapies that enhance the effectiveness of radiation therapy for cancer treatment. The company operates in the life sciences sector, specializing in the research and development of sensitizers, which are designed to improve the efficacy of radiation therapy. By leveraging cutting-edge technology and scientific research, Shuttle Pharmaceuticals aims to offer solutions that enhance cancer treatment outcomes.

How the Company Makes Money

Shuttle Pharmaceuticals Holdings, Inc. generates revenue primarily through the development and commercialization of its proprietary radiation sensitizer products. The company may also engage in strategic partnerships and collaborations with research institutions, pharmaceutical companies, and clinical centers to advance its product pipeline and expand its market reach. Revenue streams can include licensing agreements, milestone payments, and potential sales of its products upon regulatory approval. Additionally, the company might receive funding through grants and research contracts that support its scientific research and development efforts.

Shuttle Pharmaceuticals Holdings, Inc. Financial Statement Overview

Summary

Shuttle Pharmaceuticals Holdings, Inc. is experiencing severe financial distress with no revenue generation and significant ongoing losses. The balance sheet is weak with high liabilities compared to assets, and cash flows are negative, indicating cash burn. The company needs to address revenue growth and cost management to improve financial health.

Income Statement

The company has reported zero revenue over the years, indicating no sales activity or product commercialization. The net profit margin and other profitability metrics are negative due to ongoing losses. This reflects a challenging financial position with no revenue stream and increasing expenses.

Balance Sheet

The balance sheet shows a negative equity position in some years, indicating potential insolvency risks. The debt-to-equity ratio is not meaningful due to negative equity. The company is heavily reliant on debt, which poses financial stability risks.

Cash Flow

The cash flow statement shows a negative free cash flow consistently, indicating the company is burning cash without generating incoming cash flows. The operating cash flow to net income ratio is negative due to losses, highlighting unsustainable cash operations.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
0.00	0.00	0.00	0.00	0.00
	Gross Profit
0.00	-6.81K	-66.83K	-60.83K	-54.95K
	EBIT
-7.70B	-5.89M	-2.55M	-1.74M	-509.52K
	EBITDA
-7.70B	-3.99M	-4.32M	-1.04M	-711.15K
	Net Income Common Stockholders
-9.14B	-6.59M	-3.10M	-1.20M	-845.36K
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
1.92B	5.46M	8.42M	504.75K	117.15K
	Total Assets
2.51B	5.95M	8.65M	651.64K	544.05K
	Total Debt
1.65B	1.09M	748.30K	978.88K	815.82K
	Net Debt
-268.55M	-1.49M	-7.67M	474.13K	698.66K
	Total Liabilities
1.80B	1.90M	975.68K	2.28M	2.23M
	Stockholders Equity
709.15M	4.06M	7.68M	-1.63M	-1.69M
Cash Flow		Free Cash Flow
-7.33B	-5.60M	-2.71M	-300.34K	-37.65K
	Operating Cash Flow
-7.33B	-5.58M	-2.71M	-300.34K	-26.83K
	Investing Cash Flow
2.92B	-2.83M	0.00	0.00	-10.82K
	Financing Cash Flow
3.76B	2.57M	10.62M	687.93K	70.07K

Shuttle Pharmaceuticals Holdings, Inc. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.26
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SHPH, the sentiment is Negative. The current price of 0.26 is below the 20-day moving average (MA) of 0.37, below the 50-day MA of 0.49, and below the 200-day MA of 1.32, indicating a bearish trend. The MACD of -0.06 indicates Positive momentum. The RSI at 27.27 is Positive, neither overbought nor oversold. The STOCH value of 8.47 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SHPH.

Shuttle Pharmaceuticals Holdings, Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SCNI	52 Neutral	$1.64M	6.29	99.42%	―	―	―
Sector *	50 Neutral	$5.51B	2.95	-43.70%	2.78%	16.94%	3.59%
TCRT	47 Neutral	$4.64M	―	-111.83%	―	80.00%	86.70%
INM	40 Underperform	$3.36M	―	-83.50%	―	-11.94%	56.72%
EYEN	40 Underperform	$2.35M	―	-388.03%	―	2557.10%	-9.76%
REVB	32 Underperform	$2.76M	―	-264.85%	―	―	-115.81%
SHPH	29 Underperform	$1.60M	―	-383.84%	―	―	-7.18%

Shuttle Pharmaceuticals Holdings, Inc. Corporate Events

Shuttle Pharmaceuticals Appoints New Interim CEO and CSO

On March 31, 2025, Shuttle Pharmaceuticals Holdings, Inc. announced a restructuring of its senior management, appointing Christopher Cooper as interim CEO and Dr. Anatoly Dritschilo as Chief Scientific Officer and Chairman of the Board. This restructuring aims to enhance the company’s focus on business and capital markets while allowing Dr. Dritschilo to concentrate on ongoing Phase 2 clinical trials and scientific research, with milestones set for future clinical trial phases.

Shuttle Pharma Secures $5.2M in Public Offering

On March 12, 2025, Shuttle Pharmaceuticals Holdings, Inc. entered into an Underwriting Agreement with WestPark Capital, Inc. for a public offering of common stock and pre-funded warrants, which closed the following day. The company raised approximately $5.2 million in net proceeds, intended to fund its Phase II clinical trial for its lead product candidate, Ropidoxuridine, and for marketing, working capital, and general corporate purposes. This offering also helped Shuttle Pharma comply with Nasdaq’s minimum stockholders’ equity requirement, potentially averting delisting.

Shuttle Pharmaceuticals Appoints Christopher Cooper as Co-CEO

On March 11, 2025, Shuttle Pharmaceuticals Holdings, Inc. appointed Christopher Cooper as interim Co-Chief Executive Officer to enhance its capital markets and business capabilities. Cooper, with over 27 years of experience in management and finance, will work alongside Dr. Anatoly Dritschilo, who continues as Co-CEO overseeing scientific and clinical trial activities. This strategic appointment is expected to bolster decision-making, support fundraising, and accelerate the achievement of key milestones, particularly in the ongoing Phase 2 clinical trial of Ropidoxuridine for glioblastoma treatment.

Shuttle Pharmaceuticals Enters Revolving Loan Agreement

On February 28, 2025, Shuttle Pharmaceuticals Holdings, Inc. entered into a Revolving Loan Agreement with a lender, allowing the company to access up to $2 million for general corporate purposes. The agreement includes a high interest rate of 18% per annum and necessitated significant board changes, with four directors resigning and three new directors appointed. The loan agreement also outlines plans for a public equity offering and includes various covenants and conditions, potentially impacting the company’s strategic direction and governance.